Abstract
Abstract
RT-LAMP detection of SARS-CoV-2 has been shown as a valuable approach to scale up COVID-19 diagnostics and thus contribute to limiting the spread of the disease. Here we present the optimization of highly cost-effective in-house produced enzymes, and we benchmark their performance against commercial alternatives. We explore the compatibility between multiple DNA polymerases with high strand-displacement activity and thermostable reverse transcriptases required for RT-LAMP. We optimize reaction conditions and demonstrate their applicability using both synthetic RNA and clinical patient samples. Finally, we validated the optimized RT-LAMP assay for the detection of SARS-CoV-2 in raw nasopharyngeal samples from 184 patients. We anticipate that optimized and affordable reagents for RT-LAMP will facilitate the expansion of SARS-CoV-2 testing globally, especially in sites and settings with limited economic resources.
Competing Interest Statement
VP is shareholder at Colorna AB. X. Yin is the co-founder of Biotech & Biomedicine Science Shenyang Co. Ltd.
Funding Statement
This project was primarily funded by the SciLifeLab/KAW national COVID-19 research program project grant (KAW 2020.0182). VP laboratory is supported by a Wallenberg Academy Fellowship [2016.0123], the Swedish Foundation’s Starting Grant (Ragnar Söderberg Foundation), the Swedish Research Council [VR 2016-01842], Karolinska Institutet (SciLifeLab Fellowship, SFO, KID and KI funds) and a Joint China-Sweden mobility grant (STINT, CH2018-7750). Yin laboratory is supported by 2020 LiaoNing Province Key Research Project (1580441949000), Ganzhou COVID-19 Emergency Research Project, Key Special Project of "Technology Boosts Economy 2020" of Ministry of Science and Technology (SQ2020YFF0411358) for COVID-19 related work. BR laboratory is supported by a SciLifeLab/KAW national COVID-19 research program project grant (2020.0182), the Swedish Research Council (2017-01723) and the Ragnar Söderberg Foundation (M16/17).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used pseudo-anonymized surplus material previously collected for clinical diagnostics of SARS-CoV-2. This is in accordance with the Swedish Act concerning the Ethical Review of Research Involving Humans, which allows development and improvement of diagnostic assays using patient samples which were collected to perform the testing in question. Additional ethical approval for RT-LAMP diagnosis was obtained by the appropriate Swedish Authority (Dnr 2020-01945, Etikprövningsnämnden).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data provided as supplementary table.
